Cyclotek is excited to announce a significant expansion of our radiopharmaceutical manufacturing operations in Queensland, designed to meet the growing needs of imaging and therapy centres across the state. Our new facility in Mansfield will complement our existing operations at the Princess Alexandra Hospital, significantly enhancing our production capacity and supply chain resilience. Scheduled to commence operations Q1 2026, the facility will more than double our output of key PET tracers 18F-FDG and 18F-PSMA, while enabling a new capacity for first in human and phase II clinical trials of novel radiopharmaceuticals in Queensland. Additionally, the combination of the GE HealthCare PETtrace 890 cyclotron and FASTlabs with Comecer hot cells, have been selected for their reliability, high uptime, and sustainable production capabilities. By investing in Queensland, Cyclotek is not only addressing immediate healthcare needs but also laying the foundation for long-term collaborations that will drive economic growth and innovation in the sector.
Greg Santamaria, CEO of Cyclotek, commented “As the demand for PET/CT services continues to increase, this expansion positions Cyclotek as a reliable partner for imaging and therapy centres across Queensland.” He added, “By building our second facility, we’re not just increasing capacity, we’re ensuring our customers have a dependable, uninterrupted supply of radiopharmaceuticals, no matter where they are.” The increasing prevalence of PET/CT installations, particularly in regional areas, has significantly increased the demand for radiopharmaceuticals. Cyclotek’s new 1,200m² (13,000 ft2) facility is designed to address this demand, providing imaging providers with a consistent, reliable source of these critical tracers essential for the diagnosis of cancer and neurological disease. With the addition of this second facility, we can ensure that every imaging and therapy centre in Queensland has access to the radiopharmaceuticals needed to serve their patients.
This new investment ensures that imaging centres throughout Queensland will have access to a steady, timely supply of radiopharmaceuticals, enabling them to deliver optimal patient care without delays. In addition to supporting diagnostic imaging, the new facility will also expand Cyclotek’s role in clinical trial manufacture and supply of theranostic agents. Cyclotek has a proven track record of introducing advanced tracers to Australia, including a successful MSAC application for PSMA PET/CT, leading to Medicare rebate for prostate cancer patients nationwide. “Imaging centres are no longer just diagnostic hubs, they’re becoming integral to the future of personalized medicine and targeted therapies,” stated Dr. Rob Ware, Cyclotek’s Chief Medical Officer. “Our Mansfield facility is designed to facilitate this transition, ensuring providers are well-equipped to integrate cutting-edge theranostic treatments as they become available.”
“As we continue to grow alongside our imaging partners, this expansion underscores our commitment to providing a reliable, scalable, and future-ready supply chain,” concluded Santamaria. “Cyclotek is not just a supplier, we’re a long-term partner in the evolving landscape of medical imaging.”
For further information, please contact: Mr Greg Santamaria – enquiries@cyclotek.com
Cyclotek is a global leader and innovator in the radiopharmaceutical industry. We are dedicated to providing radiopharmaceuticals of the highest quality and reliability, manufactured in compliance with rigorous global standards. Our mission is to ensure healthcare providers have the best tools available for precise diagnostics and therapies, ultimately improving patient care and outcomes.
At the heart of Cyclotek is a steadfast commitment to our customers. We understand that their needs and growth aspirations are central to our operations, and we work relentlessly to support them in every possible way. From cutting-edge manufacturing facilities to unparalleled customer service, every aspect of our business is designed with this commitment in mind.
We are more than just a manufacturing company; we are an innovation hub, continuously driving advancements in the radiopharmaceutical field. We believe in the transformative power of innovation, and we are dedicated to pushing boundaries, challenging norms, and pioneering breakthroughs.
Above all, Cyclotek stands for quality, reliability, customer focus, and innovation. Our customers, their patients, and the radiopharmaceutical industry as a whole can depend on our commitment to these values as we strive to make a positive impact on healthcare across the globe.
[contact-form-7 id=”714″ title=”Update Form”]
